William E. Boden, MD
Dr. William E. Boden is Professor of Medicine at Boston University School of Medicine and Lecturer in Medicine, Harvard Medical School, in Boston, Massachusetts. In July 2016, Dr. Boden returned to the VA Boston Healthcare System to assume new duties as the Physician Research Lead for the New England VA Healthcare System and as the Scientific Director of the Clinical Trials Network, which is based at the VA Boston campus. He is also a Senior Investigator at the VA Boston’s Massachusetts Veterans Epidemiology, Research, and Informatics Center (MAVERIC). Dr. Boden has previously held academic appointments as Professor of Medicine at Upstate Medical University, Syracuse, NY; University of Connecticut School of Medicine, Farmington, CT; University at Buffalo Schools of Medicine and Public Health, Buffalo, NY; and Albany Medical College, Albany, NY
Dr. Boden received his M.D. degree from State University of New York, Upstate Medical University, Syracuse, N.Y. in 1974. He performed his Internal Medicine residency training at Boston University Medical Center, followed by fellowship training in Cardiology at Tufts University School of Medicine in Boston, Massachusetts. He is board-certified in both Internal Medicine and in the subspecialty of Cardiovascular Disease. Since 1979, Dr. Boden has held university academic appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, Albany Medical College, and currently at Boston University School of Medicine and Harvard Medical School.
Dr. Boden’s principal research interests include studies in stable ischemic heart disease, post-myocardial infarction (MI) secondary prevention, acute coronary syndromes, and dyslipidemia in post-MI and coronary artery disease (CAD). He has worked extensively in the clinical trials arena of non-ST-segment elevation MI and in assessing the role of calcium antagonists in patients with ischemic heart disease, notably in non-Q-wave MI secondary prevention. Dr. Boden has been involved in clinical research investigator activities as the project director, study chairman and co-chairman for multicenter clinical trials, and served as a principal investigator, steering committee member, and consultant for numerous clinical research grant activities funded by the Department of Veterans Affairs, the NIH, and industry. He was the study chairman for the VANQWISH, INTERCEPT, and more recently, the landmark COURAGE Trial (the largest randomized trial comparison of percutaneous coronary intervention [PCI] versus optimal medical therapy in stable CAD patients). He was also the study co-chairman of the NIH-funded AIM-HIGH trial evaluating the long-term role of combination dyslipidemic therapy (niacin and statin vs statin) in CAD patients with low HDL-cholesterol, and is a national co-PI on the NIH-funded ISCHEMIA Trial, a large prospective, international RCT in 5,179 patients with moderate to severe ischemia, which was published in the NEJM in April, 2020 and is a landmark trial.
Dr. Boden has lectured widely (both nationally and internationally) and has written over 450 peer-reviewed publications, original articles, books, chapters, and abstracts. He has been selected as one of the Best Doctors in America continuously since 2003. He is a member of several professional Cardiology organizations and editorial boards. He is an Associate Editor of the European Heart Journal and a member of the editorial board of the Journal of the American College of Cardiology, American Journal of Cardiology, and Journal of Cardiovascular Pharmacology and Therapeutics. He serves as an ad hoc reviewer for the New England Journal of Medicine, the Lancet, Journal of the American Medical Association, JAMA Cardiology, Circulation, American Heart Journal, Journal of Clinical Lipidology, Annals of Internal Medicine, JAMA Internal Medicine, American Journal of Medicine, Clinical Cardiology, and World Journal of Cardiology.
Aruna D. Pradhan, MD, MPH
Dr. Aruna D. Pradhan is Associate Professor of Medicine at Harvard Medical School, associate physician in the Division of Preventive Medicine (DPM), Brigham and Women’s Hospital and staff cardiologist in the Division of Cardiovascular Diseases, VA Boston Healthcare System. Dr. Pradhan’s research focus over the past 15 years has been the evaluation of novel inflammatory and lipid biomarkers and novel drug therapy in type 2 diabetes (T2D), coronary and peripheral artery disease (PAD). She is or has been the recipient of numerous research grants sponsored by the American Heart Association, National Institutes of Health and industry. She is currently Principal Investigator of several large ongoing studies serving as co-Principal Investigator of the multinational PROMINENT trial of pemafibrate to reduce cardiovascular events in T2D patients with hypertriglyceridemia. Dr. Pradhan is Immediate-Past Chair of the American Heart Association’s Council on Peripheral Vascular Diseases. She completed her cardiovascular medicine fellowship at the Brigham and Women’s Hospital in 2004 and subspecialty training in echocardiography at the Massachusetts General Hospital in 2005.